HC Wainwright Has Bearish Forecast for ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Investment analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued on Thursday, February 27th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of $0.70 for the year, down from their previous forecast of $1.21. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2026 earnings at $1.88 EPS, FY2027 earnings at $2.05 EPS and FY2028 earnings at $2.18 EPS.

Several other analysts also recently weighed in on ACAD. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective for the company. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.00.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $18.26 on Monday. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $24.27. The company has a 50-day simple moving average of $18.44 and a 200-day simple moving average of $16.88. The firm has a market capitalization of $3.04 billion, a PE ratio of 23.41 and a beta of 0.37.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several institutional investors have recently modified their holdings of ACAD. Summit Investment Advisors Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 12,519 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 795 shares during the last quarter. Quest Partners LLC lifted its position in ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,047 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in ACADIA Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,066 shares during the period. Arete Wealth Advisors LLC raised its stake in ACADIA Pharmaceuticals by 15.9% during the fourth quarter. Arete Wealth Advisors LLC now owns 13,700 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 1,875 shares in the last quarter. Finally, KBC Group NV raised its stake in ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 2,044 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.